Enzymatic synthesis and mechanistic insights into the hepatoprotective effects of α-monoglucosyl rutin against cyclophosphamide-induced liver injury: a multi-omics approach
Jing Tian , Yanfeng Zhao , Fanghang Li , Yezhu Xu , Wenting Yi , Su Jiang , Yunping Tang , Yun Lu
{"title":"Enzymatic synthesis and mechanistic insights into the hepatoprotective effects of α-monoglucosyl rutin against cyclophosphamide-induced liver injury: a multi-omics approach","authors":"Jing Tian , Yanfeng Zhao , Fanghang Li , Yezhu Xu , Wenting Yi , Su Jiang , Yunping Tang , Yun Lu","doi":"10.1016/j.intimp.2025.115265","DOIUrl":null,"url":null,"abstract":"<div><div>Rutin has attracted widespread attention due to its multiple pharmacological activities, but inherent defects such as poor water solubility and low bioavailability have greatly limited its clinical applications. Therefore, this study employed cyclodextrin glucanotransferase (CGTase) to catalyze the glycosylation modification of rutin, preparing rutin derivatives with improved water solubility. After optimizing the conditions, we isolated and purified 98.33 % of high-purity α-monoglucosyl rutin (α-GR), and its structure was also characterized. Subsequently, the cyclophosphamide (CTX)-induced murine liver injury model was used for activity evaluation. Our results showed that α-GR could significantly reduce liver function indicators (AST, ALT, and TBA), regulate antioxidant enzyme activities and inflammatory factor levels, and effectively attenuate CTX-induced liver injury. Furthermore, integrated metabolomics, transcriptomics, and RT-PCR analyses indicated that α-GR primarily exerts its hepatoprotective effects by intervening in key metabolites and gene expressions in CTX metabolic processes, related inflammatory responses, and oxidative stress pathways. Our results show that α-GR can effectively repair liver damage caused by CTX, thus laying the foundation for its use as a dietary supplement or therapeutic adjuvant.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"163 ","pages":"Article 115265"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S156757692501255X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Rutin has attracted widespread attention due to its multiple pharmacological activities, but inherent defects such as poor water solubility and low bioavailability have greatly limited its clinical applications. Therefore, this study employed cyclodextrin glucanotransferase (CGTase) to catalyze the glycosylation modification of rutin, preparing rutin derivatives with improved water solubility. After optimizing the conditions, we isolated and purified 98.33 % of high-purity α-monoglucosyl rutin (α-GR), and its structure was also characterized. Subsequently, the cyclophosphamide (CTX)-induced murine liver injury model was used for activity evaluation. Our results showed that α-GR could significantly reduce liver function indicators (AST, ALT, and TBA), regulate antioxidant enzyme activities and inflammatory factor levels, and effectively attenuate CTX-induced liver injury. Furthermore, integrated metabolomics, transcriptomics, and RT-PCR analyses indicated that α-GR primarily exerts its hepatoprotective effects by intervening in key metabolites and gene expressions in CTX metabolic processes, related inflammatory responses, and oxidative stress pathways. Our results show that α-GR can effectively repair liver damage caused by CTX, thus laying the foundation for its use as a dietary supplement or therapeutic adjuvant.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.